Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...
The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.
WEST HAVEN, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Cellinfinity Bio, a privately held pioneer biotechnology company developing first/best-in-class cell therapy products against solid tumors and other ...